Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Teva Pharmaceutical Industries Limited    TEVA   IL0006290147

News SummaryMost relevantAll newsSector newsTweets

Teva Pharmaceutical Industries : Comments on Anticipated At Risk U.S. Launch of Generic Glatiramer Acetate 40mg,mL and Launch of Generic Glatiramer Acetate 20mg, mL

share with twitter share with LinkedIn share with facebook
share via e-mail
10/06/2017 | 12:45pm CET

Release date- 05102017 - JERUSALEM - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today commented that any launch by Mylan of a generic version of COPAXONE 40mg/ml (glatiramer acetate) prior to final resolution of the pending patent appeals and other patent litigation should be considered an 'at risk' launch, which could subject Mylan to significant damages among other remedies.

Additionally, Mylan also announced approval of a generic glatiramer acetate 20mg/mL.

'We have planned for the eventual introduction of a generic competitor to glatiramer acetate,' said Dr. Yitzhak Peterburg, Teva's Interim President and CEO. 'We remain confident in patient and physician loyalty to Teva's COPAXONE due to its recognized efficacy, safety and tolerability profile, and we will continue to promote and support the product. As we are closing the third quarter, it is too soon to officially comment on any change to our full year business outlook.'

Two appeals will be argued before a single panel of judges of the U.S. Court of Appeals for the Federal Circuit. In the first case, Teva is appealing the December 2016 inter partes review decisions of the Patent Trial Appeal Board that found all of the claims of three COPAXONE patents to be unpatentable. In the second case, Teva is appealing the January 2017 decision of the U.S. District Court for the District of Delaware, which declared certain claims of four COPAXONE patents invalid. The two appeals have been fully briefed and await the scheduling of oral arguments. In additional litigation, Teva brought suit against five Abbreviated New Drug Application (ANDA) filers, including Mylan, for infringement of a patent covering a manufacturing process for glatiramer acetate product.

Due to the anticipated launch of another generic 20mg glatiramer acetate product and the anticipated launch of a first generic 40mg glatiramer acetate product, Teva's early assessment of the impact of these launches to its earnings for the fourth quarter ended December 31, 2017 is that it could be affected by at least $0.25 cents per share. These conditions are subject to change based on the discount; adoption rate and other factors of the competitive products. Teva will provide additional details on its 3rd Quarter Earnings Conference Call onNovember 2, 2017.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in over 60 markets every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were $21.9 billion.


Tel: 215-591-8912

(c) 2017 Electronic News Publishing -, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
01/17 TEVA PHARMACEUTICAL INDUSTRIES : FDA approves Teva leukemia treatment
01/16 TEVA PHARMACEUTICAL INDUSTRIES : Announces U.S. FDA Approval of TRISENOX Injecti..
01/16 TEVA PHARMACEUTICAL INDUSTRIES : Announces U.S. FDA Approval of TRISENOX (arseni..
01/16 TEVA PHARMACEUTICAL INDUSTRIES : Embattled Teva fined NIS 75m. for bribing forei..
01/15 TEVA PHARMACEUTICAL INDUSTRIES : settles graft case with Israeli authorities
01/15 TEVA PHARMACEUTICAL INDUSTRIES : agrees future of Abic Netanya with workers
01/15 TEVA PHARMACEUTICAL INDUSTRIES : corruption settlement doesn't cover co officers
01/15 TEVA PHARMACEUTICAL INDUSTRIES : Announces U.S. FDA Approval of TRISENOX® (arsen..
01/14 TEVA PHARMACEUTICAL INDUSTRIES : Moody's cuts Teva debt to junk status
More news
News from SeekingAlpha
01/18 Generic firms under pressure on possible hospital drug-making venture
01/18 Hospital groups planning to enter generic drugs business
01/18 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 17, 2018
01/18 CTI BioPharma earns $10M milestone from Teva on U.S. OK of Trisenox
01/18 The Re-Balancing Act
Financials ($)
Sales 2017 22 633 M
EBIT 2017 6 276 M
Net income 2017 -
Debt 2017 34 419 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 2,43x
EV / Sales 2018 2,35x
Capitalization 20 637 M
Duration : Period :
Teva Pharmaceutical Indust Technical Analysis Chart | TEVA | IL0006290147 | 4-Traders
Technical analysis trends TEVA PHARMACEUTICAL INDUST
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 23,3 $
Spread / Average Target 14%
Kåre Schultz President, Chief Executive Officer & Director
Sol J. Barer Chairman
Carlo de Notaristefani President & CEO-Global Operations
Michael McClellan Chief Financial Officer & Executive Vice President
Amir Elstein Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON5.20%395 886
NOVARTIS0.61%227 592
PFIZER2.65%220 189
ROCHE HOLDING LTD.-5.40%211 135
MERCK AND COMPANY10.24%167 132